Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Cardio-Oncology Multidisciplinary Patient ASsistance Solution

Descrizione del progetto

Proteggere il cuore durante e dopo il trattamento contro il cancro

Le terapie antitumorali possono danneggiare il cuore: si tratta di una complicanza nota come cardiotossicità. La gestione di questo rischio pone sfide significative a causa della mancanza di indicatori affidabili di allerta precoce. Di conseguenza, i medici sono spesso costretti a ridurre o interrompere il trattamento contro il cancro. Il progetto COMPASS, finanziato dall’UE, affronta il problema mettendo in atto un programma completo di cardio-oncologia incentrato sul paziente. Il consorzio punta a scoprire nuovi biomarcatori, sviluppare strumenti di imaging basati sull’intelligenza artificiale e integrare tecnologie indossabili per la diagnosi precoce e la gestione personalizzata delle complicanze cardiovascolari. COMPASS unirà ricerca clinica, innovazione digitale e coinvolgimento dei pazienti per migliorare gli esiti terapeutici dei malati di cancro senza compromettere l’efficacia delle loro cure.

Obiettivo

The rise in cardiovascular disease among cancer patients and survivors, due to treatment side effects, poses a significant challenge to patient outcomes and healthcare systems. Managing cardiotoxicity is difficult due to its delayed onset and lack of reliable biomarkers, often requiring dose reduction or discontinuation of cancer treatment, which may compromise its effectiveness.

The COMPASS project aims to optimize cardiovascular health for cancer patients and survivors through a comprehensive, patient-centered clinical pathway over five years. It will advance cardio-oncology research by creating an international network and developing tools for better disease prediction, prevention, diagnosis, and management. The project focuses on integrating cardio-oncology care pathways, optimizing diagnostic biomarkers, and utilizing AI-supported imaging and wearable technologies for early detection and personalized treatment, while promoting sustainable healthcare delivery and reducing environmental impact.

COMPASS methodology includes three pillars: (i) Discovery of Novel Biomarkers and Parameters, (ii) AI Prediction Models and Clinical Decision Support System, and (iii) Improving Care Delivery and Patient Engagement. Activities across the program include Health Economics, Communication, Dissemination, Exploitation and Sustainability, and Ethics and Regulatory Aspects. This public private partnership of 51 academic and industrial partners will collaborate to translate scientific advancements into clinical applications, apply novel AI approaches, ensuring solutions are effective, meet patient needs, and align with European health policies and regulations. Key stakeholders include clinicians, nurses, patients, payers, regulators, and industry actors. COMPASS aims to advance cardio-oncology research, reduce healthcare costs, and improve patient well-being through innovative tools, collaborative networks, and policy support. Ultimately, it aims to improve patient outcomes for both cancer and heart health.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-JU-IHI-2025-09-single-stage

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

KING'S COLLEGE LONDON
Contributo netto dell'UE
€ 1 538 740,00
Indirizzo
STRAND
WC2R 2LS London
Regno Unito
Regione
London Inner London — West Westminster
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 538 740,00

Partecipanti (61)

Partner (2)